iovera

iovera° is a commercial-stage medical device company focused on non-opioid pain management through its cryoneurolysis platform. Its flagship iovera° system is FDA-cleared for blocking peripheral nerves to relieve pain for up to 90 days, with primary applications in osteoarthritis knee pain and perioperative pain management for procedures like knee replacement surgery. The company targets the significant unmet need for effective, non-pharmacological pain relief solutions amid the opioid crisis. As a private company, it commercializes its device directly to healthcare professionals in outpatient settings.

Proprietary cryoneurolysis system that uses precisely controlled extreme cold (nitrous oxide) to temporarily block peripheral sensory nerves, inhibiting pain signal transmission for up to 90 days.

iovera° competes in the interventional pain management space against other nerve ablation technologies (e.g., radiofrequency ablation), injectable therapies (corticosteroids, hyaluronic acid), pharmacological treatments (NSAIDs, opioids), and surgical interventions. Its primary differentiation is its drug-free mechanism, immediate onset, and predictable 90-day duration of effect.